{"meshTagsMajor":["Gene Rearrangement","Precision Medicine"],"keywords":["anaplastic lymphoma kinase rearrangement","crizotinib","non-small-cell lung cancer"],"meshTags":["Animals","Antineoplastic Agents","Biomarkers, Tumor","Carcinoma, Non-Small-Cell Lung","Drug Design","Drug Resistance, Neoplasm","Gene Rearrangement","Humans","Lung Neoplasms","Molecular Targeted Therapy","Precision Medicine","Protein Kinase Inhibitors","Pyrazoles","Pyridines","Receptor Protein-Tyrosine Kinases","Signal Transduction","Treatment Outcome"],"meshMinor":["Animals","Antineoplastic Agents","Biomarkers, Tumor","Carcinoma, Non-Small-Cell Lung","Drug Design","Drug Resistance, Neoplasm","Humans","Lung Neoplasms","Molecular Targeted Therapy","Protein Kinase Inhibitors","Pyrazoles","Pyridines","Receptor Protein-Tyrosine Kinases","Signal Transduction","Treatment Outcome"],"genes":["tyrosine kinase"],"publicationTypes":["Journal Article","Research Support, Non-U.S. Gov\u0027t","Review"],"abstract":"Crizotinib, the first clinically designed and synthesized as a tyrosine kinase inhibitor targeting mesenchymal-epithelial transition factor, indicating marked anticancer activity in patients with advanced, anaplastic lymphoma kinase-positive non-small-cell lung cancer, was approved by the US Food and Drug Administration in 2011. In this review, we focus on the efficacy of crizotinib compared with chemotherapy in advanced anaplastic lymphoma kinase-positive lung cancer and present the role of crizotinib as a personalized alternative in previously treated patients with non-small-cell lung cancer. ","title":"Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer.","pubmedId":"26491259"}